Version June 2024
| Author, year | n | Percent optimally cytoreduced* | HIPEC agents | Overall survival | Favorable prognostic factors | Preoperative morbidity and mortality |
| Yan T, 2009 | 401 | 46 | Cisplatin and Dox; cisplatin, MMC, or both | Median 53 months (range 1 to 235) Five-year: 47% | Epithelioid subtype Negative LNs Optimal CCR HIPEC | 31%/2% |
| Alexander HR, 2013 | 211 | 53 | Cisplatin or MMC | Median 38 months Five-year: 41% | Histologic grade Optimal CCR Age <60 y Cisplatin HIPEC | 30%/2.3% |
| Baratti D, 2013 | 108 | 66 (estimated) | Cisplatin and Dox | Median 63 months Five-year estimated: 50% | Epithelioid subtype Neg LNs Low mitotic rate | 39%/1.9% |
| Schaub NP, 2013 | 104 | 66 | Cisplatin | Median 52 months (range 1 to 81) Five-year: 46% | Epithelioid subtype Low PCI Low pre-op CA-125 | N/A |
| Hommell-Fontaine J, 2013 | 28 | 70 | Cisplatin and MMC | Median 37 months | <5% GLUT-1 expression | N/A |
| Magge D, 2014 | 65 | 86 | MMC (94%) | Median 46 months Five-year: 39% | Younger age Low PCI Optimal CCR Histologic grade No post-op sepsis | 35%/6% |
| Shetty S, 2014 | 44 | 81 | Carboplatin or MMC | Five-year: 53% | Carboplatin versus MMC | -/0% |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
